INmune Bio (INMB) Stock Price
INmune Bio Price
Revenue at INmune Bio has contracted by 70.6% per year over the past 6 years to 50,000.00 USD. For INmune Bio, the net margin of -91,866.0% is down versus -16,762.4% a few years ago. The consensus 12-month price target for INmune Bio is 5.61 USD, about 201.6% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.
INmune Bio stock price
INmune Bio business model & stock analysis
Frequently asked questions about INmune Bio
INmune Bio Inc is a pharmaceutical company specializing in developing innovative therapies to enhance the innate immune system for treating cancer and neurodegenerative diseases. Founded in 2015, INmune Bio has gained recognition for its focus on personalized medicine and pioneering solutions. The company aims to revolutionize the field of immunotherapy using its proprietary technologies, such as the DN-TNF vaccine, which targets tumor growth and reduces inflammation. With a strong commitment to research and development, INmune Bio is devoted to improving patient outcomes and tackling unmet medical needs. This dedication has positioned the company as a key player in the biotechnology industry.
INmune Bio Inc's business model focuses on developing novel immunotherapies to combat cancer and neurodegenerative diseases. The company utilizes a unique approach called DN-TNFα-based cancer immunotherapy, which harnesses the power of the immune system to target and eliminate cancer cells. INmune Bio's therapies aim to enhance immune responses and provide long-term protection against tumor growth. The company also conducts research on neuroinflammation and neurodegeneration with the goal of developing therapies to treat Alzheimer's and Parkinson's diseases. By leveraging cutting-edge science, INmune Bio Inc aims to revolutionize the field of immunotherapy and improve patient outcomes in the fight against cancer and neurodegenerative disorders.
INmune Bio Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of INmune Bio Inc in the market are Immune Pharmaceuticals Inc, Innovus Pharmaceuticals Inc, and Immunomedics Inc.
INmune Bio Inc has achieved several significant milestones. The company successfully completed its Phase I clinical trial for its drug candidate INB03, demonstrating its safety and tolerability in patients with advanced solid tumors. INmune Bio also received Fast Track designation from the U.S. FDA for its lead drug candidate, XPro1595, for the treatment of Alzheimer's disease. Furthermore, the company has received grant funding from the National Institutes of Health (NIH) to support the clinical development of XPro1595. These achievements highlight the progress and potential of INmune Bio Inc in the field of immunotherapy and positions them as a key player in addressing challenging diseases like Alzheimer's.
INmune Bio Inc is primarily present in the United States.
INmune Bio Inc represents a strong commitment to innovation and advancing the field of immunotherapy. The company is guided by a corporate philosophy centered around harnessing the power of the immune system to develop novel treatments for cancer and other diseases. INmune Bio Inc strives to deliver cutting-edge therapies that can make a significant impact on patients' lives. With a focus on precision medicine and personalized immunotherapies, the company is dedicated to providing hope and improved outcomes for individuals facing challenging medical conditions. INmune Bio Inc's values of integrity, scientific excellence, and patient-centricity drive their pursuit of groundbreaking solutions in the field of immunotherapy.
Analysts currently set an average price target of 5.36 USD for the INmune Bio stock (median: 5.61 USD), implying +187.9 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the INmune Bio stock: 9 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the INmune Bio share trades at 1.66 EUR (1.86 USD).
The INmune Bio share (INMB) is listed on 1 stock exchanges, including: NASDAQ (INMB).
INmune Bio Inc is a biopharmaceutical company that focuses on researching and developing novel immunotherapy products. The company is based in La Jolla, California and works with an experienced team of scientists and researchers to develop innovative solutions for diseases such as Alzheimer's, cancer, and autoimmune diseases. The business model of INmune Bio Inc includes various divisions that aim to develop immunotherapies. One of the main divisions is the research of drugs that support and enhance the body's natural immune response. The company has developed several products based on this research, including INKmune, XPro1595, and INB03. INKmune® is a unique immune activator that supports the immune system in fighting diseases such as cancer and Alzheimer's. The medication aims to activate the immune system and strengthen the body's defenses to destroy cancer cells and Alzheimer's plaques. XPro1595 is a potential medication for treating neuroinflammations that occur in Alzheimer's disease and other neurodegenerative diseases. It has been successfully used in clinical trials and proven to be effective. INB03 is an antibody that inhibits the protein CD47, which cancer cells use as a shield to protect themselves from the body's immune response. INB03 was developed to strengthen the body's immune system and build natural immunity against cancer cells. INmune Bio Inc also has a pipeline of products in development that target the research of immunotherapy solutions for other diseases such as autism and multiple sclerosis. The company specializes in collaborating with other companies and research institutions to advance its research and product development. It has already signed a number of partnership agreements to expand its pipeline of products. INmune Bio Inc employs a broad marketing strategy to promote its products. The company utilizes digital media and various marketing channels to market its products to potential customers and healthcare organizations. Overall, INmune Bio Inc is a biopharmaceutical company specializing in the development of immunotherapeutic products for various diseases. The company has positioned itself as a leader in the research and development of immunotherapies and employs a broad marketing strategy to promote its products.
The revenue cannot currently be calculated for INmune Bio.
The expected profit of INmune Bio is -14.62 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of INmune Bio is currently -3.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the INmune Bio stock.
The P/S cannot be calculated for INmune Bio currently.
The Eulerpool Quality Score for INmune Bio is 3/10.
The ISIN of INmune Bio is US45782T1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of INmune Bio is A2PCBU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of INmune Bio is INMB. The ticker symbol is used to trade INmune Bio shares on the stock exchange.
INmune Bio stock
INmune Bio Peer Group
INmune Bio Ticker
INmune Bio FIGI
All fundamentals and in-depth analysis of INmune Bio
Our stock analysis for INmune Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of INmune Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.